BMS 303141

ATP citrate lyase (ACL) catalyzes the synthesis of acetyl-CoA and oxaloacetate using citrate, CoA, and ATP as substrates and Mg2+ as a cofactor. The ACL-dependent synthesis of acetyl-CoA is important for the de novo synthesis of fatty acids and cholesterol. Furthermore, as a key enzyme for linking glucose and lipid metabolism, ACL is thought to contribute to the Warburg effect in cancer cells. BMS 303141 is a cell-permeable, 2-hydroxy-N-arylbenzenesulfonamide that inhibits ACL with an IC50 value of 0.13 µM. At an oral dose of 100 mg/kg/day, BMS 303141 has been reported to reduce weight gain and lower plasma cholesterol, triglycerides, and glucose in a mouse model of hyperlipidemia.Formal Name: 3,5-dichloro-2-hydroxy-N-(4-methoxy[1,1'-biphenyl]-3-yl)-benzenesulfonamide. CAS Number: 943962-47-8. Molecular Formula: C19H15Cl2NO4S. Formula Weight: 424.3. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml, DMSO: 25 mg/ml, Ethanol: 15 mg/ml. lambdamax: 208, 261 nm. SMILES: O=S(NC1=CC(C2=CC=CC=C2)=CC=C1OC)(C3=C(O)C(Cl)=CC(Cl)=C3)=O. InChi Code: InChI=1S/C19H15Cl2NO4S/c1-26-17-8-7-13(12-5-3-2-4-6-12)9-16(17)22-27(24,25)18-11-14(20)10-15(21)19(18)23/h2-11,22-23H,1H3. InChi Key: SIIPNDKXZOTLEA-UHFFFAOYSA-N.